Underlines the potential of OliX Pharmaceuticals’ siRNA platform

强调OliX Pharmaceuticals的siRNA平台的潜力

South Korea-based OliX Pharmaceuticals, a leading developer of RNAi therapeutics, has raised approximately KRW 110 billion through a third-party allotment of newly issued common shares to strategic investors. The investment was jointly made by BOLD, L’Oréal’s corporate venture capital fund, and Weiss Asset Management LP, a U.S.

总部位于韩国的RNAi疗法领先开发商OliX Pharmaceuticals通过向战略投资者配售新发行的普通股，筹集了约1100亿韩元。此次投资由欧莱雅旗下的企业风险投资基金BOLD与美国Weiss Asset Management LP联合完成。

asset management firm..

资产管理公司

With the newly secured funds, the company intends to advance its ongoing siRNA-based projects in several therapeutic areas, including skin- and hair-related projects.

利用新获得的资金，公司打算推进其在多个治疗领域的正在进行中的siRNA项目，包括与皮肤和头发相关的项目。

The company also expects the investment to further strengthen its strategic partnership with L’Oréal. Through this, the company aims to reinforce its research foundation and accelerate development progress.

该公司还预计，此项投资将进一步巩固其与欧莱雅的战略伙伴关系。通过此举，公司旨在夯实其研究基础并加速研发进程。

OliX is developing therapeutics based on its proprietary core drug development platform, OASIS (OliX Advanced Small Interfering RNA System), which is designed to enhance the high gene-silencing efficiency of RNAi technology and enable tissue-specific delivery. Based on this platform, OliX is advancing locally administered RNAi therapeutics for various indications, including hair loss, age-related macular degeneration (AMD), and hypertrophic scars..

OliX 正在基于其专有的核心药物开发平台 OASIS（OliX 先进小干扰 RNA 系统）开发治疗药物，该平台旨在增强 RNAi 技术的高效基因沉默能力，并实现组织特异性递送。基于这一平台，OliX 正在推进用于多种适应症的局部给药 RNAi 疗法，包括脱发、年龄相关性黄斑变性（AMD）和增生性瘢痕。